Literature DB >> 23237497

Pemphigoid diseases.

Enno Schmidt1, Detlef Zillikens.   

Abstract

Pemphigoid diseases are a group of well defined autoimmune disorders that are characterised by autoantibodies against structural proteins of the dermal-epidermal junction and, clinically, by tense blisters and erosions on skin or mucous membranes close to the skin surface. The most common of these diseases is bullous pemphigoid, which mainly affects older people and the reported incidence of which in Europe has more than doubled in the past decade. Prognosis and treatments vary substantially between the different disorders and, since clinical criteria are usually not sufficient, direct immunofluorescence microscopy of a perilesional biopsy specimen or serological tests are needed for exact diagnosis. In eight pemphigoid diseases the target antigens have been identified molecularly, which has allowed the development of standard diagnostic assays for detection of serum autoantibodies-some of which are commercially available. In this Seminar we discuss the clinical range, diagnostic criteria, diagnostic assay systems, and treatment options for this group of diseases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237497     DOI: 10.1016/S0140-6736(12)61140-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  202 in total

1.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.

Authors:  Joost M Meijer; Gilles F H Diercks; Emma W G de Lang; Hendri H Pas; Marcel F Jonkman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

3.  A Rare Case of Pediatric Bullous Spontaneous Acute Urticaria.

Authors:  Pınar Gür Çetinkaya; Bülent Enis Şekerel; Özge Uysal Soyer; Ümit Murat Şahiner
Journal:  Med Princ Pract       Date:  2018-06-28       Impact factor: 1.927

Review 4.  [Involvement of mucous membranes in autoimmune bullous diseases].

Authors:  C Günther
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

Review 5.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

6.  Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita.

Authors:  Hiroaki Iwata; Elena Pipi; Nicole Möckel; Peter Sondermann; Artem Vorobyev; Nina van Beek; Detlef Zillikens; Ralf J Ludwig
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

7.  Malignancies in pemphigus and pemphigoid diseases.

Authors:  Franziska Schulze; Kathrin Neumann; Andreas Recke; Detlef Zillikens; Roland Linder; Enno Schmidt
Journal:  J Invest Dermatol       Date:  2015-01-05       Impact factor: 8.551

Review 8.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

Review 9.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

10.  Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.

Authors:  Sarah D Ahadome; David J Abraham; Suryanarayana Rayapureddi; Valerie P Saw; Daniel R Saban; Virginia L Calder; Jill T Norman; Markella Ponticos; Julie T Daniels; John K Dart
Journal:  JCI Insight       Date:  2016-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.